MabAsia aims to improve the lives of patients by facilitating their access to efficient and affordable biopharmaceutical products, in particular monoclonal antibodies. By retaining the core competencies in-house and collaborating with a network of world-class partners, MabAsia is building a unique platform to develop and commercialize high-quality monoclonal antibodies  for regional markets.

Subscribe to Front page feed


The 4th International Innovation and Technology Exhibition (INOTEX 2015) was held on 9-12 June 2015 in Tehran, Iran. This event displays the latest scientific and technical achievements of different countries in order to promote the scientific exchange between Iran and rest of the world. 

Scientific Articles

Scientific Article1

What Are Biosimilar Drugs?



MabAsia’s mission is to produce a number of monoclonal antibodies (mAbs) within the next 4-5 years. The first product is Adalimumab which will be available soon following the completion of its clinical trial. In addition, the initial stages of acquiring cell line technologies for some other mAbs have taken places.More